Cost-effectiveness of broadly neutralizing antibody prophylaxis for HIV-exposed infants in sub-Saharan African settings.

"COMPETING INTERESTS SRP is a consultant for Merck, Moderna, Pfizer and Dynavax and has a sponsored research programme with Moderna in the area of cytomegalovirus vaccines. All other authors declare that they have no competing interests."

"FUNDING This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development [K08HD101342 to CMD, R01HD079214 to ALC and MCW] and the International Maternal Pediatric Adolescent AIDS Clinical Trials Network [DR808 to CMD and ALC]. Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) with co‐funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH); all components of the National Institutes of Health (NIH), under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC); and by NICHD contract number HHSN275201800001I. CKC was supported, in part, by the Duke University Center for AIDS Research [5P30 AI064518]."